| 1. |
Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual Mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev, 2011, 24(2): 411-445.
|
| 2. |
Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev, 2000, 13(2): 236-301.
|
| 3. |
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis, 2005, 41(5): 634-653.
|
| 4. |
Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect, 2004, 10(Suppl 1): 31-47.
|
| 5. |
Petrikkos G, Tsioutis C. Recent advances in the pathogenesis of mucormycoses. Clin Ther, 2018, 40(6): 894-902.
|
| 6. |
Hassan MIA, Voigt K. Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors. Med Mycol, 2019, 57(Suppl_2): S245-S256.
|
| 7. |
Fu Y, Lee H, Collins M, et al. Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene. FEMS Microbiol Lett, 2004, 235(1): 169-176.
|
| 8. |
Gebremariam T, Liu M, Luo G, et al. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest, 2014, 124(1): 237-250.
|
| 9. |
Pati?o-Medina JA, Maldonado-Herrera G, Pérez-Arques C, et al. Control of morphology and virulence by ADP-ribosylation factors (Arf) in Mucor circinelloides. Curr Genet, 2018, 64(4): 853-869.
|
| 10. |
Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet, 2003, 362(9398): 1828-1838.
|
| 11. |
Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol, 2006, 44(4): 335-342.
|
| 12. |
Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect, 2019, 25(1): 26-34.
|
| 13. |
Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis, 2011, 17(10): 1855-1864.
|
| 14. |
Azie N, Neofytos D, Pfaller M, et al. The PATH (Prospective Antifungal Therapy) Alliance? registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis, 2012, 73(4): 293-300.
|
| 15. |
Almyroudis NG, Sutton DA, Linden P, et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant, 2006, 6(10): 2365-2374.
|
| 16. |
Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis, 2010, 50(8): 1101-1111.
|
| 17. |
Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis, 2010, 50(8): 1091-1100.
|
| 18. |
Lanternier F, Sun HY, Ribaud P, et al. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis, 2012, 54(11): 1629-1636.
|
| 19. |
Binder U, Maurer E, Lass-Fl?rl C. Mucormycosis--from the pathogens to the disease. Clin Microbiol Infect, 2014, 20(Suppl 6): 60-66.
|
| 20. |
馬舒君, 張芙蓉, 陶蘇江, 等. 鼻腦型毛霉病 2 例及相關文獻分析. 中國真菌學雜志, 2022, 17(2): 109-114.
|
| 21. |
Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis, 2012, 54(Suppl 1): S55-S60.
|
| 22. |
Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis, 2020, 71(6): 1367-1376.
|
| 23. |
Vironneau P, Kania R, Morizot G, et al. Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival. Clin Microbiol Infect, 2014, 20(5): O336-O339.
|
| 24. |
Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev, 2005, 18(3): 556-569.
|
| 25. |
Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon. Clin Microbiol Infect, 2009, 15(Suppl 5): 98-102.
|
